23 Skidoo: FDA’s Genomics Clampdown Gets Mixed Reviews
The FDA’s recent regulatory action against popular genomic testing company, 23andMe, is generating mixed responses among integrative clinicians. While many share regulators’ concerns over the validity of the tests and the public’s unguided use of genomic information, they also believe in peoples’ right to know how to read their genomic “Book of Life.”




